메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Leads Biolabs Announces Completion of Patient Enrollmen…

NANJING, China, Aug. 14, 2025 -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the successful completion of patient enrollment in the ongoing single-arm, pivotal registrational clinical trial (CTR20213023) for Opamtistomig (LBL-024), a novel PD-L1/4-1BB bispecific antibody. This marks the world's first registrational clinical trial evaluating an immunotherapy monotherapy for extrapulmonary neuroendocrine carcinoma (EP-NEC). The study, led by Professor Shen Lin from Peking University Cancer Hospital and conduc
- 김갑성 기자
- 2025-08-14 17:38
Clarivate Launches AI-powered Regulatory Assistant Within C…

[ 메디채널 김갑성 기자 ] Integrated into Cortellis Regulatory Intelligence, new AI capability helps regulatory teams streamline access to critical intelligence and understand requirements with ease LONDON, Aug. 14, 2025 -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the beta launch of its AI-powered Regulatory Assistant within Cortellis Regulatory Intelligence. This new capability is designed to help regulatory professionals navigate complex and evolving global requirements with greater ease, speed and confidence. Informed by customer i
- 김갑성 기자
- 2025-08-14 15:00
Medulla Expands Global Footprint with Strategic Launch in S…

SINGAPORE, Aug. 14, 2025 -- Medulla Communications Pvt. Ltd., one of the world's most awarded healthcare advertising agencies, has announced its expansion into Singapore, establishing a strategic hub to serve the Asia-Pacific region. Known for its expertise in solving healthcare challenges over 15 years, Medulla is looking to create a new super-specialist category as the first digital healthcare advertising agency in Asia. Medulla is one of the rare healthcare-specialist agencies to win the world's biggest awards for both creativity and marketing effectiveness, including Cannes
- 김갑성 기자
- 2025-08-14 13:30
Everest Medicines Announces Acceptance of the New Drug…

SHANGHAI, Aug. 14, 2025 -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the Taiwan Food and Drug Administration (TFDA) has officially accepted the New Drug Application (NDA) for VELSIPITY® (etrasimod) for the treatment of patients with moderately to severely active ulcerative colitis (UC). Building on prior approvals in Singapore, Hong Kong SAR, and Macao SAR, as well as NDA acceptance
- 김갑성 기자
- 2025-08-14 12:02
Alpha Global partners with LIO to redefine Mental Health Care…

New platform boosts patient experience and safety, reduces clinician burden, and unlocks operational insight across inpatient mental health hospitals SYDNEY, Aug. 14, 2025 -- Alpha Global, a trusted provider of technology-driven solutions for healthcare and care providers in Australia and New Zealand, today announced an exclusive distribution agreement for the newly launched LIO mental health operating platform. Jeremy Clare, Head of Product at Alpha Global, said: "We're incredibly excited to bring the second generation of mental health monitoring technology
- 김갑성 기자
- 2025-08-14 11:00
Alpha Global partners with LIO to redefine Mental Health Care…

New platform boosts patient experience and safety, reduces clinician burden, and unlocks operational insight across inpatient mental health hospitals SYDNEY, Aug. 14, 2025 -- Alpha Global, a trusted provider of technology-driven solutions for healthcare and care providers in Australia and New Zealand, today announced an exclusive distribution agreement for the newly launched LIO mental health operating platform. Jeremy Clare, Head of Product at Alpha Global, said: "We're incredibly excited to bring the second generation of mental health monitoring technology
- 김갑성 기자
- 2025-08-14 11:00
Shilpa Medicare's NorUDCA Makes History as First Approved NA…

Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a billion people affected by Non-Alcoholic Fatty Liver Disease (NAFLD) NAFLD affects 1 in 4 people globally (1.2 billion), with 188 million patients in India—most undiagnosed until irreversible damage occurs. A Breakthrough in Liver Health: NorUDCA delivers a novel dual-action mechanism, combining anti-inflammatory benefits with enhanced bile acid regulation. This innovative therapy promises to halt the progression of NAFLD to severe liver conditions such as NASH, cirrhosis,
- 김갑성 기자
- 2025-08-14 08:00
The Rainwater Charitable Foundation, Aging Mind Foundatio…

Established in 2023, the Tauopathy Challenge Workshop aims to bridge the gap in funding of novel neurodegenerative research for primary tauopathies, including Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), and Frontotemporal Dementias (FTDs). FORT WORTH, Texas, Aug. 13, 2025 -- The Rainwater Charitable Foundation, one of the largest independent funders of primary tauopathy research, in collaboration with the Aging Mind Foundation, the Alzheimer's Association, and CurePSP, announced today $2.5 million in grants to fund five innovative research projects ov
- 김갑성 기자
- 2025-08-13 20:00
BioDlink Accelerates Global Expansion with Bevacizumab La…

- BioDlink's bevacizumab injection secures marketing authorization in Colombia and Pakistan following its recent approval in Nigeria, marking key regulatory milestones in high-need emerging markets. - GMP certification in Brazil, Colombia, and Argentina spans the top three most populous countries in South America, collectively representing 71.4% of the continent's population. - Backed by a globally recognized quality system and a strong track record in monoclonal antibody, ADC/XDC, biosimilar development and manufacturing, BioDlink, in partnership with Kexing BioPharm is
- 김갑성 기자
- 2025-08-13 20:00
New Study Demonstrates Superiority of EggNest™ Complete Ra…

MINNEAPOLIS, Aug. 13, 2025 -- A recent study published in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) highlights the effectiveness of the EggNest™ Complete radiation shielding system, demonstrating its superior ability to protect all personnel in the catheterization lab from scatter radiation. The findings show that while other next-generation systems offer protection for the primary operator and assistant, the EggNest™ Complete system provides significant protection for the entire interventional team. The study, titled "Co
- 김갑성 기자
- 2025-08-13 19:30

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-08-20_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 21일 01시 40분